Roche’s Failed Alzheimer’s Drug Cleared Less Amyloid Than Hoped, Results Show

Roche Holding AG’s experimental Alzheimer’s disease drug gantenerumab was far less effective than hoped at clearing a toxic protein from the brain, according to findings from two studies that may explain why it failed when a therapy from rival Eisai Co. succe…
Read More